50 mg tablets
For palliative therapy of metastatic or locally progressive inoperable prostate cancer:
if treatment with analogues of luteinizing releasing hormone (LHG) or surgical intervention is insufficient, oral therapy is contraindicated or preferred;
to prevent the occurrence of undesirable secondary phenomena and complications that may be caused by an increase in serum testosterone levels at the beginning of treatment with LHR agonists;
for the treatment of hot flashes that occur during treatment with LHR agonists or after orchiectomy.
Decrease in sexual desire at hypersexuality and sexual deviations.